Parameter | ASD case | Control | | |
---|
n
| Median | Min-Max |
N
| Median | Min-Max |
p
| FDR (qvalue) |
---|
E2 (pg/mL) | 68 | 287.4 | 78.72–2778 | 128 | 311.9 | 55.02–1005 | 0.337 | 0.704 |
Testosterone (pg/mL) | 67 | 383.6 | 47.30–1393 | 130 | 366.3 | 80.47–1090 | 0.173 | 0.638 |
Testosterone/E2 ratio | 66 | 1.49 | 0.21–7.41 | 128 | 1.25 | 0.14–4.310 | 0.222 | 0.666 |
ER-EEQ (pg E2/mL) | 75 | 470.9 | 204.1–1308 | 135 | 545.8 | 149.0–1308 | 0.329 | 0.704 |
EDC-EEQ (pg E2/mL) | 68 | 168.5 | 0.28–1226 | 128 | 214.4 | 2.72–1165 | 0.162 | 0.638 |
AR-AEQ (pg DHT/mL) | 75 | 62.60 | 23.90–137.3 | 135 | 62.50 | 16.90–290.4 | 0.910 | 0.910 |
EDC-AEQ (pg DHT/mL) | 67 | 22.56 | 1.000–100.4 | 130 | 28.45 | 1.34–274.0 | 0.167 | 0.638 |
AR-AEQ/ER-EEQ | 75 | 0.13 | 0.02–0.48 | 135 | 0.11 | 0.02–0.98 | 0.343 | 0.704 |
EDC-AEQ/EDCs-EEQ | 61 | 0.18 | 0.01–59.10 | 117 | 0.086 | 0.003–26.21 | 0.515 | 0.764 |
T3-ThEQ (ng T3/mL) | 74 | 2.36 | 0.10–17.14 | 133 | 2.41 | 0–6.60 | 0.594 | 0.764 |
AhR-TEQ (pg TCDD/mL) | 37 | 0.24 | 0–1.310 | 51 | 0.15 | 0–2.10 | 0.907 | 0.910 |
- E2 17β-estradiol, ER-EEQ the combined effect on ER of endogenous estrogen and xeno-estrogens (EDCs) given as estradiol equivalent, EDCs-EEQ the integrated estrogenic effect induced only by xeno-estrogens (EDCs) alone given as estradiol equivalent, DHT dihydrotestosterone, AR-AEQ the combined effect on AR of endogenous androgens and xeno-androgens (EDCs) given as androgen equivalent, EDC-AEQ the integrated androgenic effect induced only by xeno-androgens (EDCs) alone given as androgen equivalent, T3 L-3,5,3′-triiiodothyronine, T3-ThEQ the combined proliferation effect (PE) of endogenous thyroid and xeno-thyroid hormone-like compounds (EDCs) given as thyroid equivalent, AhR-TEQ the combined effect on AhR of dioxin-like compounds given as TCDD equivalent, FDR (qvalue) false discovery rate. See the “Methods” section and Table 1 for the different calculations. The difference between cases and controls was compared using non-parametric Mann-Whitney test